Faslodex Registry: Fulvestrant in Current Clinical Practice
Faslodex Registry: Fulvestrant in Current Clinical Practice
The sequential administration of endocrine therapies to patients with advanced breast cancer
 requires the availability of therapies with different modes of actions, so that tumours
 developing resistance to one agent are not cross resistant to another. Because of its
 mechanism of action, fulvestrant is distinct from other hormonal therapies, which therefore
 limits the possibility of cross-resistance with other therapies such as tamoxifen and the
 aromatase inhibitors (AIs)

 -  In this way, patients may benefit from an extended period of endocrine treatment, which
 has considerable tolerability and quality-of-life advantages over cytotoxic
 chemotherapy.

 -  In Belgium, fulvestrant is indicated for treating postmenopausal women with hormone
 receptor-positive locally advanced or metastatic breast cancer with recurrence during or
 after adjuvant anti-oestrogen therapy or disease progression during anti-oestrogen
 treatment. However, little information is currently available on how fulvestrant is
 actually being used by physicians in Belgium. The optimum sequence of endocrine
 treatment for advanced breast cancer has yet to be defined and may depend on certain
 patient or disease characteristics.

 Fulvestrant has been granted reimbursement by the Belgian Health authorities (RIZIV/INAMI)
 with the recommendation to collect the real life data necessary to assess the patients'
 breast cancer treatment history that may influence the actual endocrine treatment sequence
 according to physicians current clinical practice..
Inclusion Criteria:

 -  Postmenopausal women with hormone receptor-positive locally advanced or metastatic
 breast cancer

 Exclusion Criteria: